Tag: Valneva
Valneva: an MA dossier deemed admissible by Health Canada
(CercleFinance.com) – Valneva announces that Health Canada has completed the admissibility review of the marketing authorization application (MA) for its single-shot chikungunya vaccine candidate VLA1553 for use in 18-year-olds and…
Valneva: Valneva lab publishes positive data in adolescents for its anti-chikungunya vaccine
(BFM Bourse) – The company communicated on Monday data on the safety of this vaccine while those on immunogenicity will be published in November. Valneva is taking a step towards…
Valneva: Positive data for VLA1553 in adolescents
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
Valneva: positive data from the chikungunya vaccine trial – 08/28/2023 at 08:35
Immunogenicity data from this clinical trial should be available in November 2023. (photo credit: Valneva Group / ) (AOF) – Valneva SE, a vaccines company, today announced positive early Phase…
Valneva: positive data from chikungunya vaccine trial
(AOF) – Valneva SE, a vaccines company, today announced positive early Phase 3 safety data in adolescents for its single-dose chikungunya (CHIKV) vaccine candidate, VLA1553. Immunogenicity data from this clinical…
Valneva: positive data for VLA1553 in adolescents
(CercleFinance.com) – Valneva announces positive early Phase III safety data in adolescents for its single-dose chikungunya vaccine candidate, VLA1553, data from the ongoing VLA1553-321 trial in Brazil . According to…
Valneva: positive data for VLA1553 in adolescents – 08/28/2023 at 07:22
(CercleFinance.com) – Valneva announces positive early Phase III safety data in adolescents for its single-dose chikungunya vaccine candidate, VLA1553, data from the ongoing VLA1553-321 trial in Brazil . According to…
Valneva: Undermined by the postponement of the end of the review of its anti-chikungunya vaccine, Valneva falls on the stock market
(BFM Bourse) – The specialist in vaccines against infectious diseases announced on Monday that the American health authority, the FDA, had modified the target date for the completion of this…
Valneva: target date postponed by the FDA in chikungunya – 08/14/2023 at 08:10
(CercleFinance.com) – Valneva announces that the US FDA has postponed, from the end of August to the end of November, its target date for completing the regulatory review of the…
Valneva: postponement for the regulatory review of its chikungunya vaccine candidate – 08/14/2023 at 08:10
(AOF) – Valneva, a company specializing in vaccines, today announced that the United States Food and Drug Administration (FDA) has changed the target date, as part of the Prescription Drug…
Valneva: Valneva drops after FDA delays review date for its Chikungunya vaccine
(Reuters) – Valneva shares fell on the stock market on Monday after the US Food and Drug Administration (FDA) decided to postpone the target date for the regulatory review of…
Valneva: postponement for the regulatory review of its chikungunya vaccine candidate
(AOF) – Valneva, a company specializing in vaccines, today announced that the United States Food and Drug Administration (FDA) has changed the target date, as part of the Prescription Drug…